Recompensation factors in patients with decompensated cirrhosis
Cuvinte cheie:
ciroza hepatică, decompensare, terapie antivirală, abstinența de la alcoolRezumat
Decompensated cirrhosis marks an irreversible stage in chronic liver disease. Effective etiological treatment may induce hepatic recompensation. We have evaluated the factors which contribute to the improvement of patients with decompensated liver cirrhosis. This review followed a comprehensive literature search using PubMed, Clinical Review, and Google Scholar, focusing on articles, meta-analyses, and references from relevant articles and textbooks published between 2021 and 2024. Our analysis of current literature demonstrates that antiviral therapy and alcohol cessation significantly enhance prognosis and facilitate hepatic recompensation in patients with decompensated cirrhosis. The pathophysiology of recompensation in cirrhosis involves several mechanisms: reduction of liver injury, hepatocyte regeneration, resolution of fibrosis, reduction of portal hypertension, improvement in hemodynamics (decreased cardiac output, splanchnic vasodilation, and improved vascular responsiveness). The patients who achieve HBV DNA levels <20 IU/ml during antiviral therapy experience resolution of ascites, encephalopathy, and absence of recurrent variceal bleeding for at least 12 months. Patients with HCV decompensated liver cirrhosis in case of attaining the sustained virologic response have a great chance for post-treatment recompensation. Further, patients with decompensated alcohol-related cirrhosis achieved recompensation through sustained abstinence. Recompensation has become a significant focus in the study of cirrhosis, especially in cases of chronic liver disease with known causes like viral hepatitis and alcohol consumption. Achieving recompensation in patients with virus- and alcohol-related cirrhosis is promising, but more studies are needed to understand its underlying mechanisms and clinical characteristics.
Referințe
1. ARAVINTHAN, A.D., BARBAS, A.S., DOYLE, A.C., et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. In: Transpl Int. 2017, nr. 30, pp. 1140-1149. ISBN: 978-973-115-052-9. https://doi.org/10.1111/tri.13008
2. COSTA, D., SIMBRUNNER, B., JACHS, M., et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. In: J Hepatol. 2021, nr. 74, pp. 819-828. ISBN: 978-973-115-052-9. https://doi.org/10.1016/j.jhep.2020.10.004
3. D'AMICO, G., PASTA, L., MORABITO Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. In: Aliment Pharmacol Ther. 2014, nr. 39, pp. 1180-1193. ISBN: 978-973-115-052-9. https://doi.org/10.1111/apt.12721
4. DE FRANCHIS, R., BOSCH, J., GARCIA-TSAO, G., et al. Baveno VII-Renewing Consensus in Portal Hypertension. In: Journal of Hepatology. 2022, nr. 76.4, pp. 959-974. ISSN 0168-8278.
5. EL-SHERIF, O., JIANG, Z.G. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. In: Gastroenterology. 2018, nr. 154(8), pp. 2111-2121. ISSN 0016-5085. https://doi.org/10.1053/j.gastro.2018.03.022
6. FERENCI, P., LOCKWOOD, A., MULLEN, K Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna 1998. 2002, pp. 716-721. ISBN: 978-973-115-052-9. https://doi.org/10.1053/jhep.2002.31250
7. FONTANA, R.J., HANN, H.W. Factors influencing early mortality in patients with decompensated chronic hepatitis B undergoing antiviral therapy. In: Gastroenterology. 2002, nr. 123(3), pp. 719-727. ISSN 0016-5085. https://doi.org/10.1053/gast.2002.35352
8. GENTILE, I., SCOTTO, R., COPPOLA, C., et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). In: Hepatol Int. 2019, nr. 13(1), pp. 66-74. ISBN: 978-973-115-052-9. https://doi.org/10.1007/s12072-018-9914-6
9. HE, Z., WANG, B. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multicenter observational study comparing patients with ascites and bleeding. In: Hepatol Int. 2023, nr. 17(6), pp. 1368-1377. ISSN 1936-0533. https://doi.org/10.1007/s12072-023-10579-w
10. HOFER, B.S., BURGHART, L., HALILBASIC, E., et al. Editorial: Recompensation in PBC is good. But is it good enough? In: Alimentary Pharmacology & Therapeutics. 2024, nr. 59(9), pp. 1146-1147. ISBN: 978-973-115-052-9. https://doi.org/10.1111/apt.17966
11. JACHS, M., HARTL, L., SCHAUFLER, D., et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. In: Gut. 2021, nr. 70, pp. 1758-1767. ISBN: 978-973-115-052-9. https://doi.org/10.1136/gutjnl-2020-322712
12. JANG, JEONG WON. Long-Term Effect of antiviral therapy on disease course after decompensation in patients with Hepatitis B related cirrhosis. In: Hepatology. 2015, nr. 61(6), pp. 1809-1820. ISSN 0016-5085. https://doi.org/10.1002/hep.27723
13. LACKNER, C., SPINDELBOECK, W., HAYBAECK, J., et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. In: J Hepatol. 2017, nr. 66(3), pp. 610-618. ISSN 0168-8278. https://doi.org/10.1016/j.jhep.2016.11.011
14. LENS, S., BAIGES, A., ALVARADO-TAPIAS, E., et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. In: J Hepatol. 2020, nr. 73, pp. 1415-1424. ISSN 0168-8278. https://doi.org/10.1016/j.jhep.2020.05.050
15. PASCASIO, J.M., VINAIXA, C. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. In: Journal of Hepatology. 2017, nr. 67(6), pp. 1168-1176. ISSN 0168-8278. https://doi.org/10.1016/j.jhep.2017.08.008
16. PERRICONE, G., DUVOUX, C. European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. In: Liver Int. 2018; nr. 38, pp. 2170-2177. ISSN 1478-3231. https://doi.org/10.1111/liv.13878
17. POSE, E., TORRENTS, A., REVERTER, E., et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. In: J Hepatol. 2021, nr. 75(2), pp. 275-283. ISBN: 978-973-115-052-9. https://doi.org/10.1016/j.jhep.2021.02.033
18. REIBERGER, T., FERLITSCH, A., PAYER, B.A., et al. Non-selective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. In: J Hepatol. 2013, nr. 58, pp. 911-921. ISSN 0168-8278. https://doi.org/10.1016/j.jhep.2012.12.011
19. REIBERGER, T., HOFER, B.S. The Baveno VII concept of cirrhosis recompensation. In: Digestive and Liver Disease. 2023, no. 55(4), pp. 431-441. ISSN 1590-8658. https://doi.org/10.1016/j.dld.2022.12.014
20. RIPOLL, C., BARI, K., GARCIA-TSAO, G. Serum albumin can identify patients with compensated cirrhosis with a good prognosis. In: J Clin Gastroenterol. 2015, nr. 49(7), pp. 613-619. ISBN: 978-973-115-052-9. https://doi.org/10.1097/MCG.0000000000000207
21. RIPOLL, C., GROSZMANN, R., GARCIA-TSAO, G., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. In: Gastroenterology. 2007, nr. 133, pp. 481-488. ISBN: 978-973-115-052-9. https://doi.org/10.1053/j.gastro.2007.05.024
22. SHARMA, S., ROY, A. Recompensation in cirrhosis: current evidence and future directions. In: Journal of Clinical and Experimental Hepatology. 2023, no. 13(2), pp. 329-334. ISSN 0973-6883. https://doi.org/10.1016/j.jceh.2022.08.002
23. VILLANUEVA, C., ALBILLOS, A., GENESCA, J., et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. In: J Hepatol. 2021, nr. 75, pp. 589-599. ISBN: 978-973-115-052-9. https://doi.org/10.1016/j.jhep.2021.04.022
24. VILLANUEVA, C., ALBILLOS, A., GENESCA, J., et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension: liver failure/cirrhosis/portal hypertension. In: Hepatology. 2016, nr. 63, pp. 197-206. ISBN: 978-973-115-052-9. https://doi.org/10.1002/hep.28264
25. VOROBIOFF, J., GROSZMANN, R. J., PICABEA, E., et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective study. In: Gastroenterology. 1996, nr. 111(3), pp. 701-709. ISSN 0016-5085. https://doi.org/10.1053/gast.1996.v111.pm8780575
26. WANG, Q., ZHAO, H., DENG, Y., et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. In: J Hepatol. 2022, nr. 77(6), pp. 1564-1572. ISSN 0168-8278. https://doi.org/10.1016/j.jhep.2022.07.037
27. XU, X., WANG, H. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study. In: BMJ. 2021, nr. 11(6), e043083. ISSN 2044-6055. https://doi.org/10.1136/bmjopen-2020-043083
Descărcări
Publicat
Număr
Secțiune
Licență
Această lucrare este licențiată în temeiul Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
